enGene to Participate in Upcoming Investor Conferences
enGene to Participate in Upcoming Investor Conferences
enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the following investor conferences:
Wells Fargo 21st Annual Healthcare Conference
Date: Tuesday, September 8, 2026
Time: 10:15 a.m. ET
Format: Fireside Chat
Morgan Stanley 24th Annual Global Healthcare Conference
Date: Monday, September 14, 2026
Time: 7:00 a.m. ET
Format: Fireside Chat
H.C. Wainwright 28th Annual Global Investment Conference
Date: Tuesday, September 15, 2026
Time: 1:30 p.m. ET
Format: Corporate Presentation
A live webcast of these events can be accessed on the “Events and Presentations” page under the “Investors” section of the enGene website at www.engene.com and will be archived there for 90 days.
About enGene
enGene Therapeutics Inc. is a clinical-stage biotechnology company mainstreaming non-viral genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid (also known as detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease.
Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.
To learn more, please visit enGene.com and follow us on LinkedIn, X and BlueSky.
Media and Investor Contact:
Lauren Hopfer
Lhopfer@engene.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260901720827/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
Are TIPS ETFs the Best Way to Fight Inflation?
What’s Ahead for Stocks This Quarter—and Where to Invest
10 Best Blue-Chip Stocks to Buy for the Long Term
United States